Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M and Doxorubicin in Advanced Soft Tissue Sarcoma
NCT03719430Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotigalimab in soft tissue sarcoma (STS). Primary endpoint: Objective Response Rate at 6 months. Started Mar 2019; status: completed.
02
Drugs
sotigalimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03719430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719430.